HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function o...

Full description

Saved in:
Bibliographic Details
Main Authors NGUYEN, Van N, LOPEZ, Omar D, NIMJE, Roshan Yadavrao, RAHAMAN, Hasibur, SAULNIER, Mark G, BELEMA, Makonen, WANG, Alan Xiangdong, XU, Ningning, TU, Yong, MEANWELL, Nicholas A, FRENNESSON, David B, HEWAWASAM, Piyasena, WANG, Gan, GUPTA, Samayamunthula Venkata Satya Arun Kumar
Format Patent
LanguageEnglish
French
Published 09.02.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. La présente invention concerne de manière générale des composés antiviraux et, en particulier, des associations de composés pouvant inhiber la fonction de la protéine NS5A codée par le virus de l'hépatite C (VHC), des compositions comprenant de telles associations et des méthodes d'inhibition de la fonction de la protéine NS5A.
Bibliography:Application Number: WO2016US44158